China SXT Pharmaceuticals Inc (SXTC) FinancialsSXTCChina SXT Pharmaceuticals Inc

China SXT Pharmaceuticals Inc (SXTC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Regular TCMP, accounting for 107.1% of total sales, equivalent to $547.84K. Other significant revenue streams include Others and Advanced TCMP. Understanding this composition is critical for investors evaluating how SXTC navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, China SXT Pharmaceuticals Inc maintains a gross margin of 16.23%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1011.69%, while the net margin is -1016.46%. These profitability ratios, combined with a Return on Equity (ROE) of -50.30%, provide a clear picture of how effectively SXTC converts its operational activities into shareholder value.

In the context of the broader market, SXTC competes directly with industry leaders such as BDRX and SBFM. With a market capitalization of $676.34K, it holds a significant position in the sector. When comparing efficiency, SXTC's gross margin of 16.23% stands against BDRX's N/A and SBFM's 25.35%. Such benchmarking helps identify whether China SXT Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

The financial performance is concerning, with a forward P/E of 0 and a price-to-sales ratio of 0.626, indicating low revenue relative to its market cap. The company also has a price-to-book ratio of 0.023987, suggesting it is significantly undervalued, but this is coupled with negative cash flow metrics.